This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NMED-1077; OROS Hydromorphone; Hydromorphone HCl Extended-Release; AP-77; Jurnista
Description: OROS hydromorphone is designed as a once-daily extended release form of the opioid analgesic hydromorphone.
Alza (JNJ) and Knoll (Abbott)
Alza, a subsidiary of Johnson & Johnson, had an agreement with Knoll Pharmaceuticals, a subsidiary of Abbott Laboratories, for the development and worldwide commercialization of OROS Hydromorphone.
In 2004, Alza reacquired the rights to OROS Hydromorphone from Abbott.
Neuromed and Alza (JNJ)
In April 2007, Neuromed Pharmaceuticals announced that it has licensed from Alza the exclusive U.S. rights to develop and commercialize OROS Hydromorphone in Phase III clinical development. Under the terms of the agreement Neuromed will make an upfront payment of $30 million, additional regulatory milestone payments, and will pay royalties based on commercial sales of the product. Neuromed will develop and market the product in the U.S., while Alza will retain the rights to develop and market the product in other countries. Alza will manufacture the product for Neuromed as well as for other markets in which the product is sold....See full deal structure in Biomedtracker
Partners: Johnson & Johnson EPIRUS Biopharmaceuticals, Inc.
Additional information available to subscribers only: